Hospital
Odessa Regional Hospital LP
Odessa Regional Hospital LP was paid $7.16M by Medicaid between Aug 2020 and Dec 2024, across 96 billing codes. Its largest line is 99284, emergency room visit (serious) — 45% of everything it billed.
33Billing provider infoODESSA REGIONAL HOSPITAL LP
ODESSA, TX 79761
ODESSA, TX 79761
33aNPI1801852736assigned 04/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.16M
24GClaims99,268
24DCodes billed96
24AFirst – last monthAug 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#22 of 109
Median peer was paid$1.15M
This provider vs. median6.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,385 | $118K | |
| 2021 | 23,716 | $1.46M | |
| 2022 | 29,781 | $2.13M | |
| 2023 | 29,155 | $2.29M | |
| 2024incomplete | 14,231 | $1.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 45% | 7,139 | 6,812 | $3.23M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 23% | 3,343 | 3,117 | $1.61M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 12,537 | 12,246 | $1.23M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.5% | 5,235 | 5,109 | $179K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.1% | 10,423 | 5,109 | $152K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 3,184 | 3,128 | $80K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.1% | 726 | 709 | $76K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,655 | 2,606 | $65K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,855 | 2,679 | $56K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 992 | 921 | $44K |
| 80053 | Comprehensive metabolic panel | <1% | 5,483 | 5,031 | $39K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,686 | 2,621 | $33K |
84 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,237 | $31K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,041 | $29K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 291 | $28K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 701 | $27K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 68 | $26K |
| 87807 | <1% | 1,505 | $25K | |
| G0378 | Hospital observation service, per hour | <1% | 28 | $15K |
| 90715 | <1% | 182 | $13K | |
| 81025 | <1% | 1,750 | $11K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 911 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,570 | $9K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 502 | $9K |
| 87081 | <1% | 1,657 | $8K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 90 | $8K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 352 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,442 | $7K |
| 81003 | <1% | 3,610 | $6K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 25 | $5K |
| 84484 | <1% | 954 | $5K | |
| 80047 | <1% | 558 | $5K | |
| 59025 | Fetal non-stress test | <1% | 31 | $4K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 261 | $4K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 100 | $4K |
| 83690 | <1% | 893 | $4K | |
| 81001 | <1% | 1,554 | $3K | |
| 83605 | <1% | 457 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 49 | $3K |
| 87428 | <1% | 280 | $3K | |
| 81404 | <1% | 15 | $3K | |
| 85610 | <1% | 1,080 | $3K | |
| 85730 | <1% | 639 | $2K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 71 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 331 | $2K |
| 83789 | <1% | 102 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 219 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 424 | $2K |
| 84145 | <1% | 90 | $2K | |
| 82261 | <1% | 70 | $2K | |
| 81402 | <1% | 15 | $1K | |
| 83021 | <1% | 55 | $1K | |
| 90686 | <1% | 41 | $1K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 14 | $1K |
| 83491 | <1% | 55 | $1K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 273 | $1K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 41 | $1K |
| 82776 | <1% | 70 | $1K | |
| 83020 | <1% | 55 | $921.90 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,844 | $893.58 |
| 83498 | <1% | 15 | $840.43 | |
| 83516 | <1% | 55 | $825.85 | |
| 90674 | <1% | 14 | $814.41 | |
| 81479 | Unlisted molecular pathology procedure | <1% | 71 | $703.20 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 180 | $690.44 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 69 | $664.39 |
| 84437 | <1% | 70 | $662.75 | |
| 82726 | <1% | 15 | $611.01 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 12 | $599.72 |
| 83520 | <1% | 15 | $534.36 | |
| 82016 | <1% | 15 | $510.04 | |
| 83919 | <1% | 15 | $509.00 | |
| 86141 | <1% | 42 | $487.17 | |
| 82128 | <1% | 15 | $429.02 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 137 | $368.44 |
| 84702 | <1% | 30 | $366.56 | |
| S3620 | Newborn metabolic screening panel, includes test kit, postage and the laboratory tests specified by the state for inclusion in this panel (e.g., galactose; hemoglobin, electrophoresis; hydroxyprogesterone, 17-d; phenylalanine (pku); and thyroxine, total) | <1% | 114 | $347.35 |
| 81401 | <1% | 15 | $337.13 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 193 | $253.78 |
| 86140 | <1% | 46 | $249.58 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 342 | $236.29 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 14 | $217.33 |
| 87040 | <1% | 31 | $213.30 | |
| 83735 | <1% | 41 | $178.40 | |
| 83880 | <1% | 15 | $170.38 | |
| 85027 | <1% | 26 | $149.77 | |
| 36416 | <1% | 50 | $93.27 | |
| 87186 | <1% | 12 | $90.88 | |
| 85007 | <1% | 25 | $87.22 | |
| 88720 | <1% | 12 | $72.33 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 34 | $21.10 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 18 | $17.17 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 46 | $7.25 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 42 | $0.00 |
| A9270 | Non-covered item or service | 0% | 546 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBROWN, STACEY (HOSPITAL CEO)
| Provider | Location | Paid |
|---|---|---|
| Family Service of the Piedmont, INC. | High Point, NC | $1.99M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.